Cynthia Ma

Cynthia Ma

UNVERIFIED PROFILE

Are you Cynthia Ma?   Register this Author

Register author
Cynthia Ma

Cynthia Ma

Publications by authors named "Cynthia Ma"

Are you Cynthia Ma?   Register this Author

100Publications

2989Reads

7Profile Views

PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer.

Oncotarget 2019 Jun 4;10(38):3667-3680. Epub 2019 Jun 4.

Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557212PMC
June 2019

Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.

Breast Cancer Res Treat 2019 Apr 2;174(2):443-452. Epub 2019 Jan 2.

Washington University School of Medicine, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05106-7DOI Listing
April 2019

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer.

FASEB J 2019 02 30;33(2):1644-1657. Epub 2018 Aug 30.

Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.

View Article

Download full-text PDF

Source
https://www.fasebj.org/doi/10.1096/fj.201801241R
Publisher Site
http://dx.doi.org/10.1096/fj.201801241RDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338642PMC
February 2019

Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis.

Clin Breast Cancer 2018 10 27;18(5):e997-e1002. Epub 2018 Jun 27.

Washington University Brown School of Public Health, St. Louis, MO; Section of Medical Oncology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.06.013DOI Listing
October 2018

Long-term outcomes of APBI via multicatheter interstitial HDR brachytherapy: Results of a prospective single-institutional registry.

Brachytherapy 2018 Jan - Feb;17(1):171-180. Epub 2017 Oct 28.

Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2017.09.009DOI Listing
July 2018

Neoadjuvant Endocrine Therapy: Who Benefits Most?

Surg Oncol Clin N Am 2018 01;27(1):121-140

Department of Surgery, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2017.07.008DOI Listing
January 2018

Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.

Cancer 2017 Aug 25;123(16):3125-3131. Epub 2017 Apr 25.

Brown School, Washington University in St. Louis, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30722DOI Listing
August 2017

The role of neratinib in HER2-driven breast cancer.

Future Oncol 2017 Jun 30. Epub 2017 Jun 30.

Division of Oncology, Department of Medicine, Washington University in Saint Louis, St Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0186DOI Listing
June 2017

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

J Clin Oncol 2017 Apr 3;35(10):1061-1069. Epub 2017 Jan 3.

Matthew J. Ellis and Chad J. Creighton, Baylor College of Medicine; Gildy Babiera and Kelly Hunt, MD Anderson Cancer Center, Houston; Gary Unzeitig, Doctor's Hospital of Laredo, Laredo; Marilyn Leitch, University of Texas Southwestern Campus, Dallas, TX; Vera J. Suman, Mayo Clinic, Rochester MN; Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Cynthia X. Ma, and D. Craig Allred, Washington University School of Medicine, St Louis; Timothy Pluard, St Lukes Hospital, Kansas City, MO; Michael Barnes, Roche Diagnostics, Mountain View; Laura Esserman, University of California San Francisco, San Francisco, CA; Mitchell Dowsett, Royal Marsden Hospital, London, UK; G. Thomas Budd, Cleveland Clinic; Paula Silverman, Case Western Reserve University, Cleveland OH; Eric Winer, Dana-Farber Cancer Institute, Boston MA; Lisa Carey, University of North Carolina, Chapel Hill; David Ota, Duke University, Durham, NC; Pat Whitworth, Nashville Breast Center, Nashville, TN; J. Michael Guenther, St Elizabeth Medical Center, Edgewood, KY; Zoneddy Dayao, University of New Mexico, Albuquerque, NM; and John A. Olson Jr, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455353PMC
April 2017

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.

Breast Cancer Res Treat 2017 02 3;161(3):491-499. Epub 2016 Dec 3.

Division of Oncology, Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-4062-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243212PMC
February 2017

Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.

Am Soc Clin Oncol Educ Book 2016 ;35:e40-54

From the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of San Francisco School of Medicine, San Francisco, CA; Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159198DOI Listing
January 2017

Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.

Adv Exp Med Biol 2016 ;882:125-54

Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, 320A Cullen, MS 600, 77030, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-22909-6_5DOI Listing
August 2016

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.

Oncotarget 2016 Aug;7(35):56864-56875

Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/10870
Publisher Site
http://dx.doi.org/10.18632/oncotarget.10870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302958PMC
August 2016

Chemotherapy principles of managing stage IV breast cancer in the United States.

Chin Clin Oncol 2016 Jun 14;5(3):42. Epub 2016 Apr 14.

Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA. Email:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2016.04.01DOI Listing
June 2016

Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.

Ann Surg Oncol 2015 Nov 18;22(12):3861-5. Epub 2015 Mar 18.

Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-015-4487-2DOI Listing
November 2015

HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.

J Natl Compr Canc Netw 2015 Sep;13(9):1061-4

From the Department of Oncology, Kaplan Medical Center, Rehovot, Israel; Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, and Washington University School of Medicine, St. Louis, Missouri; and Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. From the Department of Oncology, Kaplan Medical Center, Rehovot, Israel; Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, and Washington University School of Medicine, St. Louis, Missouri; and Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. From the Department of Oncology, Kaplan Medical Center, Rehovot, Israel; Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, and Washington University School of Medicine, St. Louis, Missouri; and Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.jnccn.org/content/13/9/1061.full.pdf
Web Search
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701428PMC
http://dx.doi.org/10.6004/jnccn.2015.0131DOI Listing
September 2015

Cognitive impairment after chemotherapy related to atypical network architecture for executive control.

Oncology 2015 7;88(6):360-8. Epub 2015 Feb 7.

Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, St. Louis, Mo., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000370117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449788PMC
August 2015

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.

Pharmacogenet Genomics 2015 Aug;25(8):377-81

aDepartment of Medicine, Washington University School of Medicine, St Louis, Missouri bDepartment of Medicine, Baylor College of Medicine cDepartment of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas, USA dDepartment of Medicine, Universita' Campus Bio-Medico di Roma, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498982PMC
August 2015

US breast cancer mortality trends in young women according to race.

Cancer 2015 May 5;121(9):1469-76. Epub 2014 Dec 5.

Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409464PMC
May 2015

Mechanisms of aromatase inhibitor resistance.

Nat Rev Cancer 2015 May;15(5):261-75

Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston 77030, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3920DOI Listing
May 2015

The oncogenic role of the cochaperone Sgt1.

Oncogenesis 2015 May 18;4:e149. Epub 2015 May 18.

1] Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA [2] Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/oncsis.2015.12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450263PMC
May 2015

Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.

Breast Cancer Res Treat 2015 Apr 12;150(2):231-42. Epub 2015 Mar 12.

Division of Medical Oncology & Hematology, Department of Medicine, Loma Linda University, 11175 Campus Street, CSP 11015, Loma Linda, CA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-015-3316-4DOI Listing
April 2015

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

J Clin Oncol 2015 Jan 15;33(3):265-71. Epub 2014 Dec 15.

Vered Stearns, Kimmel Cancer Center, Johns Hopkins, Baltimore, MD; Judith-Anne W. Chapman, Aurélie Le Maitre, Jessica Kundapur, and Lois E. Shepherd, NCIC Clinical Trials Group, Queen's University, Kingston; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and University of Toronto, Toronto, Ontario, Canada; Cynthia X. Ma, Siteman Cancer Center, Washington University, St Louis, MO; Matthew J. Ellis, Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; James N. Ingle, Mayo Clinic, Rochester, MN; G. Thomas Budd, Cleveland Clinic, Cleveland, OH; George W. Sledge, Stanford University, San Francisco, CA; Pedro E.R. Liedke and Paul E. Goss, Harvard University; Paul E. Goss, Avon International Breast Cancer Research Program, Massachusetts General Hospital, Boston, MA; Manuela Rabaglio, Inselspital University Hospital and International Breast Cancer Study Group Coordinating Center, Berne, Switzerland; and Pedro E.R. Liedke, Hospital de Clínicas de Porto Alegre and Instituto do Cancer Mãe de Deus, Oncologia, Porto Alegre, Rio Grande do Sul, Brazil.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/3/265.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.6926
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.57.6926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289722PMC
January 2015

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).

J Clin Oncol 2014 Dec 27;32(35):3959-66. Epub 2014 Oct 27.

Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.7941DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251959PMC
December 2014

Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer.

Clin Cancer Res 2014 Dec;20(23):5964-75

Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322416PMC
December 2014

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.

Cancer Chemother Pharmacol 2014 Aug 11;74(2):419-26. Epub 2014 Jun 11.

Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8056, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2493-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112045PMC
August 2014

Body mass index, diabetes, and triple-negative breast cancer prognosis.

Breast Cancer Res Treat 2014 Jul 29;146(1):189-97. Epub 2014 May 29.

Department of Biology, University of Virginia, Charlottesville, VA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3002-yDOI Listing
July 2014

Incorporating genomics into breast cancer clinical trials and care.

Clin Cancer Res 2013 Dec;19(23):6371-9

Authors' Affiliation: Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0837DOI Listing
December 2013

The Cancer Genome Atlas: clinical applications for breast cancer.

Oncology (Williston Park) 2013 Dec;27(12):1263-9, 1274-9

View Article

Download full-text PDF

Source
December 2013

Targeted therapy for breast cancer.

Am J Pathol 2013 Oct 27;183(4):1096-1112. Epub 2013 Aug 27.

Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2013.07.005DOI Listing
October 2013

Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.

Mol Cancer Ther 2013 Aug 20;12(8):1665-75. Epub 2013 May 20.

Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University in St Louis, School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742690PMC
August 2013

Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.

J Oncol 2013 1;2013:219869. Epub 2013 Aug 1.

Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/219869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747378PMC
August 2013

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Breast Cancer Res Treat 2013 May 19;139(1):145-53. Epub 2013 Apr 19.

Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, P.O. Box 8056, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2528-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517667PMC
May 2013

Adjuvant chemotherapy decisions in clinical practice for early-stage node-negative, estrogen receptor-positive, HER2-negative breast cancer: challenges and considerations.

J Natl Compr Canc Netw 2013 Mar;11(3):246-50; quiz 251

Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, California 92354, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0036DOI Listing
March 2013

Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells.

Breast Cancer Res Treat 2013 Feb 8;138(1):109-18. Epub 2012 Jun 8.

Department of Surgery, Washington University School of Medicine, Box 8109-3328 CSRB, 660 South Euclid Avenue, Saint Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-012-2110-9
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2110-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656506PMC
February 2013

Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Cancer Discov 2013 Feb 7;3(2):224-37. Epub 2012 Dec 7.

Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0349DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570596PMC
February 2013

Racial differences in outcomes of triple-negative breast cancer.

Breast Cancer Res Treat 2013 Feb 12;138(1):281-9. Epub 2013 Feb 12.

Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-2397-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537526PMC
February 2013

Phase II trial of temsirolimus in patients with metastatic breast cancer.

Breast Cancer Res Treat 2012 Nov 13;136(2):355-63. Epub 2012 Jan 13.

The University of Chicago Medical Center, 5841 South Maryland Ave., MC 2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1910-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3658119PMC
November 2012

A high-throughput screen for the identification of improved catalytic activity: β-carotene hydroxylase.

Methods Mol Biol 2012 ;892:255-68

Fermentation and Metabolic Engineering Group, Ocean Nutrition Canada Ltd., Dartmouth, NS, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-61779-879-5_15DOI Listing
September 2012

Molecular basis of triple negative breast cancer and implications for therapy.

Int J Breast Cancer 2012 2;2012:217185. Epub 2011 Nov 2.

Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/217185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262606PMC
August 2012

The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept.

Oncology (Williston Park) 2012 Aug;26(8):696-7, 700

Department of Medicine, Division of Hematology , Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.

View Article

Download full-text PDF

Source
August 2012

Comparative analysis of β-carotene hydroxylase genes for astaxanthin biosynthesis.

J Nat Prod 2012 Jun 22;75(6):1117-24. Epub 2012 May 22.

Fermentation and Metabolic Engineering Group, Ocean Nutrition Canada Ltd., 101 Research Drive, Dartmouth, Nova Scotia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/np300136tDOI Listing
June 2012

Efficient extraction of canthaxanthin from Escherichia coli by a 2-step process with organic solvents.

Bioresour Technol 2012 May 6;111:276-81. Epub 2012 Feb 6.

Fermentation and Metabolic Engineering Group, Ocean Nutrition Canada Ltd., 101 Research Drive, Dartmouth, Nova Scotia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biortech.2012.01.155DOI Listing
May 2012

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

J Clin Invest 2012 Apr 26;122(4):1541-52. Epub 2012 Mar 26.

Section of Breast Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110-1093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI58765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314455PMC
April 2012

Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.

Future Oncol 2012 Mar;8(3):273-92

Washington University School of Medicine in Saint Louis, Department of Medicine, Divisions of Hematology & Oncology, St Louis, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.12.8DOI Listing
March 2012

Molecular profiling of triple negative breast cancer.

Breast Dis 2010 ;32(1-2):73-84

Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BD-2010-0309DOI Listing
February 2012

Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer.

Nat Rev Clin Oncol 2012 Feb 28;9(4):223-9. Epub 2012 Feb 28.

Breast Oncology Section, Washington University in St Louis, Campus Box 8056, 660 South Euclid Avenue, St Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2012.21
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2012.21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518447PMC
February 2012

PARP inhibitors and their evolving role in breast cancer.

Oncology (Williston Park) 2011 Oct;25(11):1033-4

Division of Hematology/Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.

View Article

Download full-text PDF

Source
October 2011

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.

Steroids 2011 Jul 21;76(8):750-2. Epub 2011 Mar 21.

Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.steroids.2011.02.023DOI Listing
July 2011

Estrogen and progesterone receptors in breast cancer.

Authors:
Cynthia X Ma

Clin Adv Hematol Oncol 2011 May;9(5):385-6

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
May 2011

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Breast Cancer Res 2011 Mar 1;13(2):R21. Epub 2011 Mar 1.

Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Lira 85, 4th floor, Santiago 8330023, Chile.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219179PMC
March 2011

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.

Trends Mol Med 2011 Feb 17;17(2):88-96. Epub 2010 Nov 17.

Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2010.10.009DOI Listing
February 2011

Neoadjuvant endocrine therapy for breast cancer.

Surg Oncol Clin N Am 2010 Jul;19(3):627-38

Division of Oncology, Department of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2010.04.004DOI Listing
July 2010

Predicting endocrine therapy responsiveness in breast cancer.

Oncology (Williston Park) 2009 Feb;23(2):133-42

Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

Source
February 2009

Letrozole in the neoadjuvant setting: the P024 trial.

Breast Cancer Res Treat 2007 3;105 Suppl 1:33-43. Epub 2007 Oct 3.

Medical Oncology, Washington University, Campus Box 8056, 660 Euclid Ave, St Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-007-9701-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001223PMC
February 2008

Femara and the future: tailoring treatment and combination therapies with Femara.

Breast Cancer Res Treat 2007 3;105 Suppl 1:105-15. Epub 2007 Oct 3.

Medical Oncology, Washington University, 660 Euclid Ave, Campus Box 8056, St Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-007-9697-2
Publisher Site
http://dx.doi.org/10.1007/s10549-007-9697-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001220PMC
February 2008